| CAS NO: | 478-01-3 |
| 包装: | 20mg |
| 市场价: | 1500元 |
| Storage | Store at -20°C |
| M.Wt | 402.39 |
| Cas No. | 478-01-3 |
| Formula | C21H22O8 |
| Solubility | ≥40.2 mg/mL in DMSO; insoluble in H2O; ≥2.43 mg/mL in EtOH with ultrasonic |
| Chemical Name | 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one |
| Canonical SMILES | COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Nobiletin是ERK抑制剂，具有浓度依赖特征[1]。
Nobiletin是一种从柑橘类水果中分离的柑橘多甲氧基黄酮，在体外和动物研究的抗炎、抗肿瘤侵袭、增殖和癌转移中扮演重要角色。
Nobiletin具有抑制肿瘤生长和癌转移的功能。在人类鼻咽癌细胞系（HONE-1和NPC-BM）中，nobiletin处理可抑制ERK1/2磷酸化，显著抑制细胞侵袭[2]。在大鼠C6胶质瘤细胞中，nobiletin可抑制ERK活性，从而抑制细胞增殖[1]。
在5-min BCCAO诱导脑缺血的小鼠模型中，nobiletin（50 mg/kg）腹腔内给药连续7天可显著抑制海马CA1神经元中迟发性神经元死亡，改善情景记忆[3]。在MPTP诱导的帕金森氏症小鼠模型中，Nobiletin（50 mg/kg i.p.）腹腔内给药连续2周可改善运动和认知缺陷[4]。
在人类单核THP-1细胞中，nobietin在100 μM浓度时可阻断TPA增强的ERK1/2活化[5]。
参考文献：
[1]. Aoki, K., et al., Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells. Biol Pharm Bull, 2013. 36(4): p. 540-7.
[2]. Chien, S.Y., et al., Nobiletin inhibits invasion and migration of human nasopharyngeal carcinoma cell lines by involving ERK1/2 and transcriptional inhibition of MMP-2. Expert Opin Ther Targets, 2015: p. 1-14.
[3]. Yamamoto, Y., et al., Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. Brain Res, 2009. 1295: p. 218-29.
[4]. Yabuki, Y., et al., Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience, 2014. 259: p. 126-41.
[5]. Eguchi, A., A. Murakami, and H. Ohigashi, Nobiletin, a citrus flavonoid, suppresses phorbol ester-induced expression of multiple scavenger receptor genes in THP-1 human monocytic cells. FEBS Lett, 2006. 580(13): p. 3321-8.
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |